Latest Articles about LGND

SPPI Acquires Late-Stage Candidate - Analyst Blog

Zacks Equity Research — Tue, 19 Mar 2013 02:45:44 Z

Spectrum Pharmaceuticals ( SPPI ) recently acquired global development and commercialization rights to Ligand Pharmaceuticals Inc 's ( LGND ) Captisol-enabled, propylene glycol-free

Glaxo's Promacta Label Expanded - Analyst Blog

Zacks Equity Research — Tue, 20 Nov 2012 21:20:01 Z

GlaxoSmithKline ( GSK ) recently announced that the US Food and Drug Administration (FDA) has approved an additional indication for Promacta (eltrombopag), also known as Revolade in the EU

Upcoming BioPharma Catalyst Trades to Consider

Trefis Team — Thu, 15 Nov 2012 22:32:17 Z

Submitted by Scott Matusow as part of our contributors program . Trading Biophama stocks before a catalyst event - if done correctly - can be a very profitable proposition, but if

The Medicines Co. Halts MDCO-2010 - Analyst Blog

Zacks Equity Research — Tue, 09 Oct 2012 02:35:01 Z

The Medicines Company ( MDCO ) recently discontinued an ongoing study being conducted with its phase II pipeline candidate - MDCO-2010. MDCO-2010 was being developed for the reduction of

MDCO's Cangrelor Enrollment by 4Q - Analyst Blog

Zacks Equity Research — Wed, 04 Jul 2012 01:39:01 Z

The Medicines Company ( MDCO ) recently announced that patient enrollment for its pivotal phase III CHAMPION PHOENIX trial is expected to finish in the fourth quarter of 2012. The study is

Glaxo Aims to Expand Promacta Label - Analyst Blog

Zacks Equity Research — Fri, 01 Jun 2012 21:15:01 Z

GlaxoSmithKline ( GSK ) recently announced that it has submitted marketing applications for Promacta (eltrombopag), known as Revolade in the EU and other countries. The company has

Is the Stock Market Overheated? Here's my Plan...

David Sterman — Mon, 26 Mar 2012 21:00:00 Z

As themarket rises steadily higher, it's getting harder to find true bargains. And though a wide range of good stocks still have reasonably-pricedshares , any market pullback would send most

A Low-Risk Pick for my $100,000 Real-Money Portfolio

David Sterman — Thu, 09 Feb 2012 20:00:00 Z

I've been thinking about biotech stocks a great deal lately. The sector seems to be trading much better in the early weeks of 2012, with a few spectacular gainers already in the bag and

3 "Insider" Stocks to Watch this Earnings Season

David Sterman — Fri, 21 Oct 2011 21:00:00 Z

While many investors moved to the sidelines in August and September, the market slide was no deterrent to officers and directors at many companies. Insider-buying was robust throughout the